Scientific studies have demonstrated how Ozoile can induce controlled oxidative stress, stimulating cells' endogenous antioxidant defenses without compromising essential cellular processes. This controlled stress helps maintain cellular redox balance, preventing the accumulation of harmful free radicals. OZOILE's mechanism of action is based on the release of molecular oxygen with the formation of low-concentration oxidative species, which act as signaling molecules capable of regulating important molecular pathways.

This modulation of the RedOx balance not only activates cellular antioxidant defenses, but also promotes the production of growth factors, supporting wound healing, tissue regeneration, the anti-inflammatory response, and antimicrobial and antiproliferative activity.

SUPPORTING PUBLICATIONS:

CIMB-46-00557-V2

The antimicrobial action of Ozoile® is the result of controlled, moderate oxidative stress. By modulating cellular redox balance, Ozoile® triggers a cascade of biochemical reactions that leads to the release of active oxygen and endoperoxide species. These molecules selectively destabilize pathogen membranes, causing their rapid inactivation. This highly targeted mechanism prevents microorganisms from adapting and developing resistance, making Ozoile® particularly effective in the treatment of acute and chronic skin infections, even when conventional treatments are ineffective. Furthermore, the modulated release of oxygen helps improve local wound oxygenation, supporting healing processes and reducing the risk of chronic infection.

SUPPORTING PUBLICATIONS:

ANTIFUNGAL ACTIVITY OF OZOILE CLINICAL CASE

BJSTR.MS.ID.007516

EVALUATION STUDY OF THE RIGENOMA PRESIDIO WITH OZOILE

Ozoile® acts physiologically by modulating cellular redox balance in a controlled manner. It induces mild and temporary oxidative stress that activates internal antioxidant defenses, without altering essential cellular functions.

The anti-inflammatory effect observed after the application of Ozoile® is the result of this redox regulation, which initiates a cascade of intracellular signals and selectively reduces the production of pro-inflammatory cytokines , such as TNF-α and IL-1β , involved in chronic inflammatory processes and the formation of hypertrophic scars .

Specific studies have shown that Ozoile® is able to reduce local inflammation , preserving the integrity of the extracellular matrix and limiting damage to healthy tissue.

The biological significance of this cascade mechanism has been confirmed by comparative studies with topical corticosteroids : in particular, the comparison with 0.1% mometasone furoate has shown that the efficacy of Ozoile® in containing inflammation is statistically significant and comparable to that of the corticosteroid, however without the side effects typical of traditional treatments.

The indirect anti-inflammatory effect of Ozoile® was further demonstrated in vitro on human colon epithelial cells (HT-29) and on immune cells (THP-1), where a reduction in the expression of TNF-α, IL-1β and ICAM-1 was observed, resulting in the containment of the inflammatory response and protection of tissue integrity .

This regulatory action , without systemic effects, promotes more physiological and harmonious healing , making Ozoile® a natural and innovative solution in supporting tissue repair processes.

A clinical study on 180 patients suffering from chronic shoulder osteoarthritis , conducted in collaboration between the University of Naples Federico II and the G. Rummo Hospital in Benevento, demonstrated that the topical use of Ozoile® brings significant benefits compared to NSAIDs . Ozoile® can also be applied for prolonged periods , improving not only the painful symptoms but also joint mobility and muscle-tendon function , contributing to the patient's well-being and quality of life.

SUPPORTING PUBLICATIONS:

ANTI-INFLAMMATORY AND TISSUE REGENERATIVE EFFECTS OF OZOILE IN BALANITIS XEROTICA OBLITERANS

OZOILE REDUCES THE LPS-INDUCED INFLAMMATORY RESPONSE IN COLONIC EPITHELIAL CELLS AND THP-1 MONOCYTES

OZOILE VERSUS CORTICOSTEROID IN THE TREATMENT OF LICHEN SCLEROSUS

Experimental data on Ozoile® show that its controlled oxidative stress stimulates fibroblasts to migrate to the damaged area and proliferate, thus accelerating the regeneration of injured tissue. Studies confirm that Ozoile® activates the expression of numerous genes involved in tissue repair, including growth factors such as VEGF, PDGF, FGF, TGF-α, and TGF-β, essential to the regenerative process. In particular, VEGF, a powerful promoter of cutaneous angiogenesis, restores blood flow to damaged tissue, providing oxygen and nutrients necessary for cell regeneration. Clinical studies have shown that Ozoile® significantly increases VEGF expression, confirming its role in promoting an optimal regenerative environment.

Ozoile® also increases the expression of e-cadherin, a protein crucial for cell cohesion, facilitating physiological healing and reducing the risk of excessive scarring.

Ozoile® represents an innovative wound management solution, particularly suitable for patients with complex wounds. Thanks to its ability to accelerate healing, Ozoile® reduces recovery times and treatment costs, while improving patients' quality of life. Its high safety profile and the absence of side effects typical of traditional therapies make Ozoile®-based products a highly advantageous option.

SUPPORTING PUBLICATIONS:

ANTI-INFLAMMATORY AND TISSUE REGENERATIVE EFFECTS OF OZOILE IN BALANITIS XEROTICA OBLITERANS

BJSTR.MS.ID.007516

CIMB-46-00557-V2

EVALUATION STUDY OF THE RIGENOMA PRESIDIO WITH OZOILE

A recent study has highlighted new potential of Ozoile®: the moderate oxidative stress it generates, through the controlled modulation of cellular redox balance, activates a cascade of intracellular signals capable of interacting positively with the immune system and regulating cellular proliferation mechanisms in pathological contexts at risk of neoplastic transformation.

The study was conducted on cell samples derived from biopsies of children with lichen sclerosus (LS), a chronic inflammatory disease of the external genitalia. The objective was to compare the preoperative effects of Ozoile® with those of a corticosteroid (mometasone furoate 0.1%) on immune response and proliferative activity in pediatric patients undergoing circumcision.

The results showed that Ozoile® significantly reduced the expression of the markers Ki-67 and p53, key indicators of cell proliferation and oncogenic risk. Ozoile®'s ability to effectively modulate these markers while maintaining an anti-inflammatory effect comparable to that of corticosteroids confirms the value of this physiological approach.

These data suggest that Ozoile® represents a valid therapeutic alternative to corticosteroids, especially in long-term treatment, thanks to a more favorable safety profile and the absence of side effects typical of steroid drugs. The study also confirms the potential of Ozoile® as an innovative agent for the management of chronic inflammatory conditions associated with the risk of cellular degeneration, opening new clinical perspectives in dermatology and topical immunotherapy.

SUPPORTING PUBLICATIONS:
Antiproliferative activity of Ozoile®

✅ A

· Acnozoil® Cream: 1.35g/40ml

✅ B

· Banival® Cream: 0.13g/3ml

✅ D

· Dermozoil® Cream: 2.8g/100ml

· Dermozoil® Rinse-Off Cleanser: 0.3g/150ml

· Dermozoil® Fluid Cleanser: 0.45g/250ml

· Dermozoil® Hydro: 4.5g/250ml

· Dermozoil® Plus: 4g/100ml

· Dermozoil® Shampoo: 0.28g/150ml

· Dermozoil® Spray: 2g/20ml

· Dolaren® Emulgel: 2g/100ml

· Dolaren® Tape Refillable: 0.04g/pc

✅ I

· Idrozoil® Rinse-Off Cleanser: 0.33g/150ml

✅ N

· Neurofisiodol® Emulgel: 2g/100ml

✅ O

· Otorig® Drops: 2g/10ml

· Otorig® Nasal Spray: 0.2g/20ml

· Otorig® Oral Spray: 0.2g/20ml

· Ozocidina® Germ: 0.3g/80ml ~ 1.9g/500ml - 3.8g/1L - 9.5g/5L

· Ozogea® Enhancement: 42g/250ml — 84g/500ml — 168g/1L

· Ozogea® Ready-to-Use Enhancer: 2g/750ml

· Ozogea® Professional Enhancement: 840g/5L — 3360g/20L

· Ozomar® Dolor Emulgel: 2g/100ml — 4g/200ml

· Ozomar® Legs Gel: 0.5g/100ml ~ 1g/200ml

· Ozomar® New Skin: 4g/100ml

· Ozomar® Skin Regeneration Body: 2g/100ml

· Ozomar® Skin Regeneration Face: 1g/50ml

✅ P

· Podoped® Cream: 5g/100ml

· Podoped® Barrier Cream: 8g/100ml

· Podoped® Fresh: 1g/100ml

· Podoped® Hydrogel: 5g/100ml

· Podoped® Nerv: 3.3g/100ml

· Podoped® Tape: 0.06g/pc

· Podoped® Spray: 4g/20ml

· Procten® Cream: 2g/40ml

· Psozoil® Cream: 3g/100ml

✅ R

· Rigenoma® Alginate: 0.5g/pc

· Rigenoma® Cream: 4g/100ml

· Rigenoma® Barrier Cream: 6g/100ml

· Rigenoma® Rinse-Off Cleanser: 0.4g/150ml

· Rigenoma® Leave-In Cleanser: 2g/750ml — 2.6g/1L

· Rigenoma® Gauze: 0.2g/pcs 10"10 —
0.6g/pcs10"30

· Rigenoma® Hydrogel: 4g/100ml

· Rigenoma® Refillable Tape: 0.05g/pc

· Rigenoma® Spray: 3g/20ml

✅ V

· Vulvovagi® Cream: 0.14g/3ml

· Vulvovagi® Spray: 2.6g/20ml